BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

770 related articles for article (PubMed ID: 8635383)

  • 21. Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer.
    Ando S; Kimura H; Iwai N; Shima M; Ando M; Kuriyama T
    Anticancer Res; 2001; 21(4B):3085-92. PubMed ID: 11712815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CYFRA 21-1 is a useful marker for esophageal squamous cell carcinoma.
    Yamamoto K; Oka M; Hayashi H; Tangoku A; Gondo T; Suzuki T
    Cancer; 1997 May; 79(9):1647-55. PubMed ID: 9128978
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients.
    Kulpa J; Wójcik E; Reinfuss M; Kołodziejski L
    Clin Chem; 2002 Nov; 48(11):1931-7. PubMed ID: 12406978
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of serum C-reactive protein (CRP) and cytokeratin 19 fragments (Cyfra 21-1) but not carcinoembryonic antigen (CEA) in surgically treated patients with non-small cell lung cancer.
    Szturmowicz M; Rudziński P; Kacprzak A; Langfort R; Bestry I; Broniarek-Samson B; Orłowski T
    Pneumonol Alergol Pol; 2014; 82(5):422-9. PubMed ID: 25133810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preliminary evaluation of the new tumor marker, CYFRA 21-1, in lung cancer patients.
    Koga H; Eguchi K; Shinkai T; Tamura T; Ohe Y; Oshita F; Saijo N; Kondo H; Oki K; Okura H
    Jpn J Clin Oncol; 1994 Oct; 24(5):263-8. PubMed ID: 7526016
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytokeratins as serum markers in lung cancer: a comparison of CYFRA 21-1 and TPS.
    Pujol JL; Grenier J; Parrat E; Lehmann M; Lafontaine T; Quantin X; Michel FB
    Am J Respir Crit Care Med; 1996 Sep; 154(3 Pt 1):725-33. PubMed ID: 8810612
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment.
    Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J
    Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of cytokeratin fragment 19 (CYFRA 21-1), tissue polypeptide antigen (TPA) and tissue polypeptide specific antigen (TPS) as tumour markers in lung cancer.
    Stieber P; Dienemann H; Hasholzner U; Müller C; Poley S; Hofmann K; Fateh-Moghadam A
    Eur J Clin Chem Clin Biochem; 1993 Oct; 31(10):689-94. PubMed ID: 7507359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour markers CEA, NSE, SCC, TPA and CYFRA 21.1 in resectable non-small cell lung cancer.
    Foa P; Fornier M; Miceli R; Seregni E; Santambrogio L; Nosotti M; Cataldo I; Sala M; Caldiera S; Bombardieri E
    Anticancer Res; 1999; 19(4C):3613-8. PubMed ID: 10629660
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Cyfra 21-1--a new tumor marker of the cytokeratin series in differential diagnosis of lung diseases].
    Oremek GM; Seiffert UB; Siekmeier R; Kirsten R
    Med Klin (Munich); 1995 Jan; 90(1):23-6. PubMed ID: 7533887
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognosis in bronchogenic squamous cell carcinoma groups divided according to serum squamous cell carcinoma-related antigen and cytokeratin 19 fragment levels.
    Kashiwabara K; Nakamura H; Esaki T
    Clin Chim Acta; 2000 Apr; 294(1-2):105-13. PubMed ID: 10727677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of tumor markers in the cytological fluid obtained from computed tomography-guided needle aspiration biopsy for the diagnosis of non-small cell lung cancer.
    Hong YJ; Hur J; Lee HJ; Nam JE; Kim YJ; Kim HS; Kim HY; Kim SK; Chang J; Kim JH; Chung KY; Choi BW; Choe KO
    J Thorac Oncol; 2011 Aug; 6(8):1330-5. PubMed ID: 21847061
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cytokeratin fragment 19 (CYFRA 21-1) as a tumor marker in non-small cell lung cancer.
    Huang MS; Jong SB; Lin MS; Chong IW; Tsai MS; Lin HC; Hwang JJ
    Kaohsiung J Med Sci; 1996 Feb; 12(2):62-8. PubMed ID: 8709175
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Preoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I non-small cell lung cancer: external validation of a prognostic score.
    Blankenburg F; Hatz R; Nagel D; Ankerst D; Reinmiedl J; Gruber C; Seidel D; Stieber P
    Tumour Biol; 2008; 29(4):272-7. PubMed ID: 18781099
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pro-gastrin-releasing peptide (ProGRP)--a useful marker in small cell lung carcinomas.
    Stieber P; Dienemann H; Schalhorn A; Schmitt UM; Reinmiedl J; Hofmann K; Yamaguchi K
    Anticancer Res; 1999; 19(4A):2673-8. PubMed ID: 10470218
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Usefulness of the SCC, CEA, CYFRA 21.1, and CRP markers for the diagnosis and monitoring of cervical squamous cell carcinoma].
    Chmura A; Wojcieszek A; Mrochem J; Walaszek-Gruszka A; Deja R; Masłyk B; Bartnik W; Sodowski K
    Ginekol Pol; 2009 May; 80(5):361-6. PubMed ID: 19548456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An evaluation of the tumour markers, carcinoembryonic antigen (CEA), cytokeratin marker (CYFRA 21-1) and neuron-specific enolase (NSE) in the differentiation of malignant from benign solitary pulmonary lesions.
    Seemann MD; Beinert T; Fürst H; Fink U
    Lung Cancer; 1999 Dec; 26(3):149-55. PubMed ID: 10598925
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High preoperative and postoperative levels of carcinoembryonic antigen and CYFRA 21-1 indicate poor prognosis in patients with pathological Stage I nonsmall cell lung cancer.
    Duan X; Cui Y; Li H; Shi G; Wu B; Liu M; Chang D; Wang T; Kong Y
    Indian J Cancer; 2015 Dec; 52 Suppl 3():E158-63. PubMed ID: 27453414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Utility of squamous cell carcinoma antigen, carcinoembryonic antigen, Cyfra 21-1 and neuron specific enolase in lung cancer diagnosis: a prospective study from China.
    Song WA; Liu X; Tian XD; Wang W; Liang CY; Zhang T; Guo JT; Peng YH; Zhou NK
    Chin Med J (Engl); 2011 Oct; 124(20):3244-8. PubMed ID: 22088515
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biomarkers in the lung cancer diagnosis: a clinical perspective.
    Li X; Asmitananda T; Gao L; Gai D; Song Z; Zhang Y; Ren H; Yang T; Chen T; Chen M
    Neoplasma; 2012; 59(5):500-7. PubMed ID: 22668014
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.